About

About Linearis Linearis is transforming healthcare by merging artificial intelligence and biomarker analysis to enhance patient care with more precise, accessible prevention, detection, treatment of metabolic diseases including cancer, diabetes, and antimicrobial resistance. The team unites unparalleled, world-renowned experts in biomarker discovery, drug development, biopharma, and healthcare innovation. Alexandre Le Bouthillier, a serial AI entrepreneur and CEO, collaborates with Jacques Corbeil, holder of the Canada Research Chair in Medical Genomics and CSO, and Manon Boisclair, a global biopharma executive and COO/CCO. Together, they have discovered and internationally marketed medical diagnostics and treatments. Contributions from Yoshua Bengio, a co-father of modern AI and Turing Prize winner, David Wishart, curator of the Human Metabolome Database, bolster Linearis' efforts in providing the first certified industrial laboratory that combines high-throughput metabolomic analysis and AI. About Linearis Linearis is transforming healthcare by merging artificial intelligence and biomarker analysis to enhance patient care with more precise, accessible prevention, detection, treatment of metabolic diseases including cancer, diabetes, and antimicrobial resistance. The team unites unparalleled, world-renowned experts in biomarker discovery, drug development, biopharma, and healthcare innovation. Alexandre Le Bouthillier, a serial AI entrepreneur and CEO, collaborates with Jacques Corbeil, holder of the Canada Research Chair in Medical Genomics and CSO, and Manon Boisclair, a global biopharma executive and COO/CCO. Together, they have discovered and internationally marketed medical diagnostics and treatments. Contributions from Yoshua Bengio, a co-father of modern AI and Turing Prize winner, David Wishart, curator of the Human Metabolome Database, bolster Linearis' efforts in providing the first certified industrial laboratory that combines high-throughput metabolomic analysis and AI. Linearis with its tandem Ventures Fund and Laboratory is pioneering and supporting discoveries to prevent, detect, and cure metabolomic diseases including cancer & diabetes through direct investments in innovative AI-powered life sciences companies. Linearis Ventures leverage its AI and multi-omics expertise to support life science companies’ growth, accelerating their trailblazing innovation and advancing biomarkers to provide critical insights into a broad spectrum of health conditions. Linearis Labs provide services to large biobanks, CROs and BioPharma companies across their life cycle management from drug discovery, patient screening, disease prevention as well as treatment monitoring.